{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:07:38Z","timestamp":1789178858873,"version":"build-2803163510"},"reference-count":65,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin &amp; Trans Imm"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:p>Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin\u201017A (IL\u201017A), has been shown to have significant efficacy in the treatment of moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis. Blocking critical mediators of immunity may carry a risk of increased opportunistic infections. Here we present clinical and <jats:italic>in vitro<\/jats:italic> findings examining the effect of secukinumab on <jats:italic>Mycobacterium tuberculosis<\/jats:italic> infection. We re\u2010assessed the effect of secukinumab on the incidence of acute tuberculosis (TB) and reactivation of latent TB infection (LTBI) in pooled safety data from five randomized, double\u2010blind, placebo\u2010controlled, phase 3 clinical trials in subjects with moderate to severe plaque psoriasis. No cases of TB were observed after 1 year. Importantly, in subjects with a history of pulmonary TB (but negative for interferon\u2010\u03b3 release and receiving no anti\u2010TB medication) or positive for latent TB (screened by interferon\u2010\u03b3 release assay and receiving anti\u2010TB medication), no cases of active TB were reported. Moreover, an <jats:italic>in vitro<\/jats:italic> study examined the effect of the anti\u2010tumor necrosis factor\u2010\u03b1 (TNF\u03b1) antibody adalimumab and secukinumab on dormant <jats:italic>M. tuberculosis<\/jats:italic> H37Rv in a novel human three\u2010dimensional microgranuloma model. Auramine\u2010O, Nile red staining and rifampicin resistance of <jats:italic>M. tuberculosis<\/jats:italic> were measured. <jats:italic>In vitro<\/jats:italic>, anti\u2010TNF\u03b1 treatment showed increased staining for Auramine\u2010O, decreased Nile red staining and decreased rifampicin resistance, indicative of mycobacterial reactivation. In contrast, secukinumab treatment was comparable to control indicating a lack of effect on <jats:italic>M. tuberculosis<\/jats:italic> dormancy. To date, clinical and preclinical investigations with secukinumab found no evidence of increased <jats:italic>M. tuberculosis<\/jats:italic> infections.<\/jats:p>","DOI":"10.1038\/cti.2017.34","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T07:20:54Z","timestamp":1503645654000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Inhibition of IL\u201017A by secukinumab shows no evidence of increased <i>Mycobacterium tuberculosis<\/i> infections"],"prefix":"10.1002","volume":"6","author":[{"given":"Michael","family":"Kamm\u00fcller","sequence":"first","affiliation":[{"name":"Translational Medicine\u2010Preclinical Safety, Novartis Institutes for Biomedical Research  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsen\u2010Fang","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Taiwan University Hospital  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher EM","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida  Orlando FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pappachan E","family":"Kolattukudy","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida  Orlando FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Brees","sequence":"additional","affiliation":[{"name":"Translational Medicine\u2010Preclinical Safety, Novartis Institutes for Biomedical Research  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah\u2010Dine","family":"Chibout","sequence":"additional","affiliation":[{"name":"Translational Medicine\u2010Preclinical Safety, Novartis Institutes for Biomedical Research  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Jorge","family":"Safi","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Fox","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,25]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.12.003"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2016.01.001"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.08.009"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242605"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-016-0572-1"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.4A0915-428R"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200690"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1240783"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12628"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13633"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04146.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011110-130318"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3726"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3742"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.024"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2010.10.004"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00294"},{"key":"e_1_2_7_21_2","doi-asserted-by":"crossref","first-page":"TBTB2","DOI":"10.1128\/microbiolspec.TBTB2-0018-2016","article-title":"Cytokines and chemokines in Mycobacterium tuberculosis infection","volume":"4","author":"Domingo\u2010Gonzalez R","year":"2016","journal-title":"Microbiol Spectrum"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.10862.1"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2017.05.015"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003472"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.11.013"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201003-0334OC"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2008.25"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00621-06"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903332"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101377"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12130"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057997"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004099"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0809550"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00282-13"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2016.07.009"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2011.10.003"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep36923"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053657"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006077"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002093"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2016.00122"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0005"},{"key":"e_1_2_7_44_2","first-page":"41","article-title":"Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations","volume":"91","author":"Iannone F","year":"2014","journal-title":"J Rheumatol"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1571-6"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2016.10"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02202-12"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27271"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00010-14"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2016.05.006"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.76"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095939"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.10.001"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90001-2"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01515-07"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02537-14"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129744"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3299"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2013.05.012"},{"key":"e_1_2_7_60_2","first-page":"124","article-title":"Tumor necrosis factor neutralization combined with chemotherapy enhances Mycobacterium tuberculosis clearance and reduces lung pathology. Am J","volume":"2","author":"Bourigault ML","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00498"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004603"},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.4RU0416-175RR"},{"key":"e_1_2_7_64_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1424302112"},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.07.005"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-2350"}],"container-title":["Clinical &amp; Translational Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/cti.2017.34","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T17:12:27Z","timestamp":1695921147000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1038\/cti.2017.34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1038\/cti.2017.34"],"URL":"https:\/\/doi.org\/10.1038\/cti.2017.34","archive":["Portico"],"relation":{},"ISSN":["2050-0068","2050-0068"],"issn-type":[{"value":"2050-0068","type":"print"},{"value":"2050-0068","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"2017-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e152"}}